文献速递中毒与环境急症复苏、休克与脓毒症

与7-羟基帽柱木碱卡痛产品相关的致死性阿片样中毒综合征

Fatal Opioid-Like Toxidrome Associated With a 7-Hydroxymitragynine Kratom Product
RSS 订阅 · PubMed · Ann Emerg Med · 2026-10-28
一句话结论浓缩7-HMG卡痛产品单片含29 mg 7-HMG,摄入3片即可造成约87 mg暴露(为高剂量叶粉的19–87倍),可致死性阿片样中毒。

本文报告1例42岁男性,据称摄入3片商业「7-HMG」卡痛产品并饮若干啤酒后在家中死亡。尸检见口鼻涌出液体、双肺重度肺水肿、膀胱充盈,无外伤或注射用药证据。残留片剂定量含29 mg 7-HMG与0.58 mg mitragynine pseudoindoxyl、极少量mitragynine;死后血7-HMG 37.3 ng/mL、mitragynine pseudoindoxyl 76 ng/mL,加巴喷丁等药物为亚治疗浓度。与干卡痛叶粉高剂量估计含1–4.5 mg 7-HMG相比,本次摄入约87 mg 7-HMG(19–87倍)。

要点

  • 商业「7-HMG」产品单片含29 mg 7-HMG,摄入3片即约87 mg,远超高剂量干叶粉估计的1–4.5 mg。
  • 死后血7-HMG 37.3 ng/mL、mitragynine pseudoindoxyl 76 ng/mL,与致死性阿片样中毒综合征一致。
  • 尸检见双肺重度肺水肿、口鼻涌出液体、膀胱充盈,无外伤或注射用药证据。
  • 7-HMG具高μ阿片受体活性,并在体内转化为更强效的mitragynine pseudoindoxyl。
  • 新型卡痛品牌产品含纯化或化学富集生物碱,剂量远超传统制剂,是新兴风险。

适用人群与场景

  • 据称摄入商业「7-HMG」卡痛产品并饮若干啤酒的42岁男性;原文未提及纳入/排除人群或特定急诊/ICU场景。

诊断标准与关键阈值

  • 残留片剂定量:29 mg 7-HMG、0.58 mg mitragynine pseudoindoxyl、极少量mitragynine;死后血7-HMG 37.3 ng/mL、mitragynine pseudoindoxyl 76 ng/mL;加巴喷丁等药物为亚治疗浓度。

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 口鼻涌出液体、双肺重度肺水肿、膀胱充盈,无外伤或注射用药证据,提示致死性阿片样中毒综合征。

研究设计与关键结果

  • 单例病例报告:42岁男性摄入3片商业「7-HMG」产品并饮若干啤酒后死亡;残留片剂含29 mg 7-HMG与0.58 mg mitragynine pseudoindoxyl;死后血7-HMG 37.3 ng/mL、mitragynine pseudoindoxyl 76 ng/mL;本次摄入约87 mg 7-HMG,为高剂量干叶粉估计1–4.5 mg的19–87倍。

证据类型、等级与局限

  • 病例报告(单例),原文未给出证据等级或推荐强度;局限为单例、死后定量、摄入史为据称、无法确立因果。

对床旁实践的改变

  • 对摄入卡痛品牌浓缩/纯化生物碱产品者应警惕阿片样中毒,不能按传统叶粉剂量低估暴露;原文未给出具体解毒剂或处置方案。

指南或共识出处

  • Ann Emerg Med . 2026 Oct 27:S0196-0644(26)01342-9. doi: 10.1016/j.annemergmed.2026.08.746. Online ahead of print.

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

Ann Emerg Med . 2026 Oct 27:S0196-0644(26)01342-9. doi: 10.1016/j.annemergmed.2026.08.746. Online ahead of print. ABSTRACT Kratom (Mitragyna speciosa) use has increased in the United States, with the market shifting from traditional leaf preparations to concentrated products containing concentrated or chemically processed alkaloids such as 7-hydroxymitragynine (7-HMG) and mitragynine pseudoindoxyl. These formulations may deliver supraphysiologic opioid-receptor agonist doses with poorly characterized toxicity. A 42-year-old man was found dead at home after reportedly ingesting 3 tablets of a commercial "7-HMG" product and several beers. Postmortem examination revealed purge fluid at the mouth and nose, severe bilateral pulmonary edema, distended bladder, and no evidence of trauma or injection drug use. Quantitative analysis of the remaining tablet showed 29 mg 7-HMG and 0.58 mg mitragynine pseudoindoxyl, with minimal mitragynine. Postmortem blood contained 37.3 ng/mL 7-HMG and 76 ng/mL mitragynine pseudoindoxyl, whereas gabapentin and other medications were present at subtherapeutic concentrations. Compared with an estimated 1 to 4.5 mg 7-HMG in a typical high dose of dried kratom leaf powder, this ingestion delivered approximately 87 mg 7-HMG (19-fold to 87-fold greater 7-HMG exposure than a high-dose botanical leaf preparation). Given the high μ-opioid receptor activity of 7-HMG and its in vivo conversion to the even more potent opioid agonist mitragynine pseudoindoxyl, the postmortem findings are most consistent with a fatal opioid-like toxidrome associated with exposure to concentrated kratom alkaloids. This case illustrates the emerging risk posed by new kratom-branded products containing purified or chemically enriched alkaloids at doses far exceeding traditional preparations. PMID: 42949698 | DOI: 10.1016/j.annemergmed.2026.08.746

来源:PubMed · Ann Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. PubMed · Ann Emerg Med:Fatal Opioid-Like Toxidrome Associated With a 7-Hydroxymitragynine Kratom Product

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。